Managing recalcitrant hypercholesterolemia in patients on current best standard of care: Efficacy and safety of novel pharmacotherapies

A. Sahebkar, Gerald Watts

Research output: Contribution to journalLiterature review

10 Citations (Scopus)

Abstract

Residual cardiovascular risk in patients with familial hypercholesterolemia (FH) on high-intensity statin therapy with or without ezetimibe and bile acid sequestrants can potentially be addressed by using agents that can further reduce plasma LDL-cholesterol (LDL-C). Two monoclonal antibodies (mAbs; evolocumab and alirocumab) against PCSK9, an antisense oligonucleotide against ApoB100 mRNA (mipomersen; Kynmaro®) and a synthetic small-molecule inhibitor of MTTP (lomitapide; Juxtapid®) are novel lipid-modifying agents that have been shown in Phase II/III studies in FH patients to lower plasma ApoB and LDL-C with a superior efficiency compared with statin monotherapy. Moreover, these agents can modulate plasma levels of other lipid indices, such as triglycerides, HDL-cholesterol (HDL-C) and lipoprotein(a), that are not substantially affected by statins. The new agents act through increased hepatic clearance of ApoB-containing lipoproteins (PCSK9 mAbs) or reduced assembly and secretion of VLDL (mipomersen and lomitapide). Anacetrapib and evacetrapib are newer inhibitors of CETP and can enhance the catabolism of ApoB, accompanied by marked elevations in plasma HDL-C. Mipomersen has been approved by the US FDA, and lomitapide by both the FDA and EMA, as adjunctive to intensive statin therapy and a fat-modified heart-healthy diet in patients with homozygous FH; their use should be accompanied by a careful monitoring of hepatic function owing to the increased risk of hepatic steatosis. PCSK9 mAbs and newer CETP inhibitors are still under investigation but their use in clinical trials has been reported to be safe and well tolerated. © 2014 Future Medicine Ltd.
Original languageEnglish
Pages (from-to)221-233
JournalClinical Lipidology
Volume9
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Standard of Care
Hypercholesterolemia
Hyperlipoproteinemia Type II
Apolipoproteins B
Safety
Drug Therapy
evacetrapib
LDL Cholesterol
Liver
Lipids
Lipoprotein(a)
Antisense Oligonucleotides
Bile Acids and Salts
HDL Cholesterol
Lipoproteins
Triglycerides
Fats
Monoclonal Antibodies
Medicine

Cite this

@article{c7855eb2b6eb42669c33397babe82d2b,
title = "Managing recalcitrant hypercholesterolemia in patients on current best standard of care: Efficacy and safety of novel pharmacotherapies",
abstract = "Residual cardiovascular risk in patients with familial hypercholesterolemia (FH) on high-intensity statin therapy with or without ezetimibe and bile acid sequestrants can potentially be addressed by using agents that can further reduce plasma LDL-cholesterol (LDL-C). Two monoclonal antibodies (mAbs; evolocumab and alirocumab) against PCSK9, an antisense oligonucleotide against ApoB100 mRNA (mipomersen; Kynmaro{\circledR}) and a synthetic small-molecule inhibitor of MTTP (lomitapide; Juxtapid{\circledR}) are novel lipid-modifying agents that have been shown in Phase II/III studies in FH patients to lower plasma ApoB and LDL-C with a superior efficiency compared with statin monotherapy. Moreover, these agents can modulate plasma levels of other lipid indices, such as triglycerides, HDL-cholesterol (HDL-C) and lipoprotein(a), that are not substantially affected by statins. The new agents act through increased hepatic clearance of ApoB-containing lipoproteins (PCSK9 mAbs) or reduced assembly and secretion of VLDL (mipomersen and lomitapide). Anacetrapib and evacetrapib are newer inhibitors of CETP and can enhance the catabolism of ApoB, accompanied by marked elevations in plasma HDL-C. Mipomersen has been approved by the US FDA, and lomitapide by both the FDA and EMA, as adjunctive to intensive statin therapy and a fat-modified heart-healthy diet in patients with homozygous FH; their use should be accompanied by a careful monitoring of hepatic function owing to the increased risk of hepatic steatosis. PCSK9 mAbs and newer CETP inhibitors are still under investigation but their use in clinical trials has been reported to be safe and well tolerated. {\circledC} 2014 Future Medicine Ltd.",
author = "A. Sahebkar and Gerald Watts",
year = "2014",
doi = "10.2217/clp.14.14",
language = "English",
volume = "9",
pages = "221--233",
journal = "Clinical Lipidology",
issn = "1746-0875",
publisher = "Taylor & Francis",
number = "2",

}

Managing recalcitrant hypercholesterolemia in patients on current best standard of care: Efficacy and safety of novel pharmacotherapies. / Sahebkar, A.; Watts, Gerald.

In: Clinical Lipidology, Vol. 9, No. 2, 2014, p. 221-233.

Research output: Contribution to journalLiterature review

TY - JOUR

T1 - Managing recalcitrant hypercholesterolemia in patients on current best standard of care: Efficacy and safety of novel pharmacotherapies

AU - Sahebkar, A.

AU - Watts, Gerald

PY - 2014

Y1 - 2014

N2 - Residual cardiovascular risk in patients with familial hypercholesterolemia (FH) on high-intensity statin therapy with or without ezetimibe and bile acid sequestrants can potentially be addressed by using agents that can further reduce plasma LDL-cholesterol (LDL-C). Two monoclonal antibodies (mAbs; evolocumab and alirocumab) against PCSK9, an antisense oligonucleotide against ApoB100 mRNA (mipomersen; Kynmaro®) and a synthetic small-molecule inhibitor of MTTP (lomitapide; Juxtapid®) are novel lipid-modifying agents that have been shown in Phase II/III studies in FH patients to lower plasma ApoB and LDL-C with a superior efficiency compared with statin monotherapy. Moreover, these agents can modulate plasma levels of other lipid indices, such as triglycerides, HDL-cholesterol (HDL-C) and lipoprotein(a), that are not substantially affected by statins. The new agents act through increased hepatic clearance of ApoB-containing lipoproteins (PCSK9 mAbs) or reduced assembly and secretion of VLDL (mipomersen and lomitapide). Anacetrapib and evacetrapib are newer inhibitors of CETP and can enhance the catabolism of ApoB, accompanied by marked elevations in plasma HDL-C. Mipomersen has been approved by the US FDA, and lomitapide by both the FDA and EMA, as adjunctive to intensive statin therapy and a fat-modified heart-healthy diet in patients with homozygous FH; their use should be accompanied by a careful monitoring of hepatic function owing to the increased risk of hepatic steatosis. PCSK9 mAbs and newer CETP inhibitors are still under investigation but their use in clinical trials has been reported to be safe and well tolerated. © 2014 Future Medicine Ltd.

AB - Residual cardiovascular risk in patients with familial hypercholesterolemia (FH) on high-intensity statin therapy with or without ezetimibe and bile acid sequestrants can potentially be addressed by using agents that can further reduce plasma LDL-cholesterol (LDL-C). Two monoclonal antibodies (mAbs; evolocumab and alirocumab) against PCSK9, an antisense oligonucleotide against ApoB100 mRNA (mipomersen; Kynmaro®) and a synthetic small-molecule inhibitor of MTTP (lomitapide; Juxtapid®) are novel lipid-modifying agents that have been shown in Phase II/III studies in FH patients to lower plasma ApoB and LDL-C with a superior efficiency compared with statin monotherapy. Moreover, these agents can modulate plasma levels of other lipid indices, such as triglycerides, HDL-cholesterol (HDL-C) and lipoprotein(a), that are not substantially affected by statins. The new agents act through increased hepatic clearance of ApoB-containing lipoproteins (PCSK9 mAbs) or reduced assembly and secretion of VLDL (mipomersen and lomitapide). Anacetrapib and evacetrapib are newer inhibitors of CETP and can enhance the catabolism of ApoB, accompanied by marked elevations in plasma HDL-C. Mipomersen has been approved by the US FDA, and lomitapide by both the FDA and EMA, as adjunctive to intensive statin therapy and a fat-modified heart-healthy diet in patients with homozygous FH; their use should be accompanied by a careful monitoring of hepatic function owing to the increased risk of hepatic steatosis. PCSK9 mAbs and newer CETP inhibitors are still under investigation but their use in clinical trials has been reported to be safe and well tolerated. © 2014 Future Medicine Ltd.

U2 - 10.2217/clp.14.14

DO - 10.2217/clp.14.14

M3 - Literature review

VL - 9

SP - 221

EP - 233

JO - Clinical Lipidology

JF - Clinical Lipidology

SN - 1746-0875

IS - 2

ER -